ArticleFrontiers in immunology2025
Correlation study of LINC02609 and SNHG17 as prognostic biomarkers of kidney renal clear cell carcinoma and therapeutic sensitivity based on public data and
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long Non-Coding RNAs in Pathogenesis of Renal Cell Carcinoma: Epigenetic Regulation, Signaling Pathways, and Therapeutic Strategies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cuprotosis, a newly identified form of regulated cell death, has emerged as a potential therapeutic target for cancers. Kidney renal clear cell carcinoma (KIRC) is frequently metastatic at diagnosis, resulting in poor prognosis. This study aimed to identify prognostic biomarkers and construct a risk model to improve survival prediction and guide therapeutic strategies for KIRC patients. Methods: Differential expression analysis, Cox regression, and risk modeling were performed using transcriptomic and clinical data. The response to immunotherapy and the sensitivity to chemotherapy drugs were analyzed through the Tumor Immune Dysfunction and Exclusion (TIDE) database and the Genomics of Drug Sensitivity in Cancer2 (GDSC2) database. Functional validation of LINC02609 was conducted in renal carcinoma A498 cells using siRNA-mediated knockdown. Results: LINC02609 and SNHG17 were significantly upregulated in KIRC tissues and independently associated with poor overall survival. The risk model constructed using those two candidate biomarkers (LINC02609 and SNHG17) exhibited high predictive accuracy as measured by the value of area under the curve (AUC). Immune status analysis showed that high- and low-risk KIRC patients exhibited abnormalities immune landscapes. TIDE analysis suggested that the risk model was significantly correlated with multiple immunotherapy-related signatures. RNA-sequencing (RNA-seq) analysis indicated that inhibition of LINC02609 would lead to abnormal activation of the mitogen-activated protein kinases (MAPK) signaling pathway. Conclusion: The candidate biomarker LINC02609 regulates the progression of renal cell carcinoma through the MAPK signaling pathway. The risk model constructed using LINC02609 and SNHG17 was significantly correlated with multiple immunotherapy-related signatures, suggesting that it might be used for the determination of immunotherapy options in KIRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.